Valneva SE ADR (VALN)

Currency in USD
5.565
-0.085(-1.50%)
Closed·
5.6200.000(0.00%)
·
Earnings results expected in 6 days
VALN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.5105.801
52 wk Range
4.75012.180
Key Statistics
Prev. Close
5.565
Open
5.801
Day's Range
5.51-5.801
52 wk Range
4.75-12.18
Volume
5.98K
Average Volume (3m)
25.28K
1-Year Change
-36.6894%
Book Value / Share
0.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VALN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.275
Upside
+120.58%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Valneva SE ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 12.275
(+120.58% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy12.00+115.63%-New CoverageAug 11, 2026
Goldman Sachs
Sell4.90-11.95%7.50DowngradeApr 22, 2026
Guggenheim
Buy11.00+97.66%13.00MaintainApr 16, 2026
Jefferies
Buy15.00+169.54%-MaintainMar 23, 2026
Goldman Sachs
Hold8.30+49.15%6.85MaintainFeb 27, 2026

Valneva SE ADR Earnings Call Summary for Q2/2026

  • Valneva H1 2026 product sales fell 18.3% YoY to EUR 64M; operating loss widened to EUR 49.9M from EUR 16.8M amid restructuring charges.
  • Company reaffirmed FY 2026 guidance of EUR 135-150M product sales and EUR 145-160M total revenue despite weaker first-half performance.
  • Cash position strengthened to EUR 121.5M at June 30 from EUR 109.6M year-end; management targets self-sustainability starting 2027 if Lyme approved.
  • Pfizer-partnered Lyme vaccine regulatory decisions expected within 12 months; CEO emphasized 'it's all about Lyme' for company's future value.
  • H2 outlook improved by new DoD IXIARO contract, better gross margins, and 25-35% operating expense reduction from restructuring program.
Last Updated: 2026-08-13, 10:04 a/m
Read Full Transcript

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.39 / -0.21
Revenue / Forecast
40.29M / 44.17M
EPS Revisions
Last 90 days

VALN Income Statement

Compare VALN to Peers and Sector

Metrics to compare
VALN
Peers
Sector
Relationship
P/E Ratio
−3.0x−2.7x−0.2x
PEG Ratio
0.03−0.040.00
Price/Book
5.9x0.7x2.6x
Price / LTM Sales
3.3x12.9x2.7x
Upside (Analyst Target)
120.6%181.6%68.5%
Fair Value Upside
Unlock13.5%11.5%Unlock

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.73M6.17%66.28M
Other Institutional Investors
64.73M34.02%365.75M
Public Companies & Retail Investors
113.79M59.81%642.92M
Total
190.26M100.00%1.07B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Pfizer Venture Investments LLC5.02%9,554,39553,982
Frazier Life Sciences Management, LP4.34%8,251,57746,621

People Also Watch

0.0148
SHFS
-35.65%
680.20
ASMI
+4.17%
7.450
SOPH
+0.13%
4.700
KYTX
-1.26%
38.710
NDXG
-1.20%

FAQ

What Is the Valneva SE ADR (VALN) Stock Price Today?

The Valneva SE ADR stock price today is 5.565 USD.

What Stock Exchange Does Valneva SE ADR Trade On?

Valneva SE ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Valneva SE ADR?

The stock symbol for Valneva SE ADR is "VALN."

What Is the Valneva SE ADR Market Cap?

As of today, Valneva SE ADR market cap is 532.320M USD.

What Is Valneva SE ADR's Earnings Per Share (TTM)?

The Valneva SE ADR EPS (TTM) is -1.01.

When Is the Next Valneva SE ADR Earnings Date?

Valneva SE ADR will release its next earnings report on Nov 24, 2026.

From a Technical Analysis Perspective, Is VALN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Valneva SE ADR Stock Split?

Valneva SE ADR has split 0 times.

How Many Employees Does Valneva SE ADR Have?

Valneva SE ADR has 620 employees.

What is the current trading status of Valneva SE ADR (VALN)?

As of Nov 18, 2026, Valneva SE ADR (VALN) is trading at a price of 5.565 USD, with a previous close of 5.565 USD. The stock has fluctuated within a day range of 5.510 USD to 5.801 USD, while its 52-week range spans from 4.750 USD to 12.180 USD.

What Is Valneva SE ADR (VALN) Price Target According to Analysts?

The average 12-month price target for Valneva SE ADR is 12.275 USD, with a high estimate of 18 USD and a low estimate of 5.1 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +120.58% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.